Clinical Trial

Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study

Completed
View on ClinicalTrials.gov →
Summary
Bladder cancer is common tumor in which recurrence and/or progression in patients undergoing TUR has been reported to range between 30% and 80% in patients with NMIBC TCC. With evidence of E-cadherin, β-catenin and SOX4 playing a role in the development of tumors, it manifests as invasion and metastasis. In this study, we hope to develop the correlation regarding the alternation in the expression of E-cadherin, β-catenin and Sox4 in determining the recurrence, progression and up staging and their prognostic value in NMIBC.
Trial Details
NCT Number NCT07657299
Lead Sponsor Ain Shams University
Conditions Bladder Cancer, Bladder Cancer Recurrence
Enrollment 30 participants
Start Date 2022-04-01
Primary Completion 2024-06-01 (estimated)
Study Completion 2024-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-18